scholarly journals The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline

2021 ◽  
Vol 17 (S1) ◽  
Author(s):  
Nicolai Franzmeier ◽  
Rik Ossenkoppele ◽  
Matthias Brendel ◽  
Anna Rubinski ◽  
Ruben Smith ◽  
...  
2021 ◽  
Author(s):  
Nicolai Franzmeier ◽  
Rik Ossenkoppele ◽  
Matthias Brendel ◽  
Anna Rubinski ◽  
Ruben Smith ◽  
...  

2017 ◽  
Vol 57 (2) ◽  
pp. 423-436 ◽  
Author(s):  
Shea J. Andrews ◽  
Debjani Das ◽  
Kaarin J. Anstey ◽  
Simon Easteal

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Nicolai Franzmeier ◽  
Marc Suárez‐Calvet ◽  
Lukas Frontzkowski ◽  
Estrella Morenas‐Rodríguez ◽  
Gernot Kleinberger ◽  
...  

2019 ◽  
Vol 34 (6) ◽  
pp. 846-846
Author(s):  
J Osuna ◽  
K Thomas ◽  
E Edmonds ◽  
K Bangen ◽  
A Weigand ◽  
...  

Abstract Objective Early identification of those at risk for mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is critical for early intervention. Recent work shows that subtle cognitive decline (SCD), operationally-defined using sensitive neuropsychological scores, predicts progression to MCI/AD and is associated with AD biomarkers. We aimed to determine whether SCD adds unique value in predicting progression to MCI/AD above and beyond other AD risk factors. Method 547 cognitively unimpaired participants from the Alzheimer’s Disease Neuroimaging Initiative (359 without SCD; 188 with SCD) underwent neuropsychological testing and lumbar puncture. Participants were classified as SCD if they performed >1 SD below the demographically-adjusted mean on 1) two neuropsychological total scores in different cognitive domains, or 2) two memory test process scores (e.g., intrusion errors), or 3) one total score and one process score. Cox regressions examined whether SCD status predicted progression to MCI and AD within 5 years after adjusting for age, education, sex, MMSE, depressive symptoms, ischemia risk, apolipoprotein E genotype, and AD biomarker “positivity” based on the cerebrospinal fluid phosphorylated tau-to-β-amyloid ratio. Results SCD status predicted progression to MCI (HR = 2.74, 95% CI = 2.07-3.63, p < .001) and AD (HR = 2.20, 95% CI = 1.04-4.65, p = .04) within 5 years, even after including known AD risk factors in the model. Conclusion SCD conveys a 2-3 fold increased risk of progression to MCI/AD and is a unique predictor above and beyond risk factors that are commonly used in preclinical AD research. These findings support our novel SCD criteria as a cost-effective and non-invasive method for identifying those at risk for future cognitive decline.


2006 ◽  
Vol 14 (7S_Part_27) ◽  
pp. P1432-P1432
Author(s):  
Yasmin Mossavar-Rahmani ◽  
Martin J. Sliwinski ◽  
Mindy J. Katz ◽  
Pamela A. Shaw ◽  
Jonathan G. Hakun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document